1 1

Jakavi 20 mg (Ruxolitinib)

Jakavi 20 mg (Ruxolitinib)

Brand Name: Jakavi
Origin: Switzerland / manufacturing origin may vary by market.
Small Orders: YES/AVAILABLE
Tags: 20mg Tablet , Blood Disorder Treatment , Cancer Medicine , Graft Versus Host Disease , GVHD Treatment , JAK inhibitor , JAK1 Inhibitor , JAK2 Inhibitor , Jakavi 20mg , Jakavi Tablet , Myelofibrosis Treatment , Novartis , Oncology Medicine , Polycythemia Vera Treatment , Prescription Medicine , Ruxolitinib , Ruxolitinib 20mg , Targeted Therapy
View full details
  • Details
  • Description
Packaging Size: 14 or 56 tablets; multipacks of 168 tablets may also be available.
Strength: 20 mg
Composition: Ruxolitinib 20 mg (as ruxolitinib phosphate) per tablet.
Treatment: Myelofibrosis, polycythemia vera, and certain cases of graft-versus-host disease (GVHD), according to the applicable indication
Form: Tablet
Brand: Jakavi
Quantity Unit: 1 tablet
Manufacturer: Novartis; manufacturing sites vary by market.

Jakavi 20 mg (Ruxolitinib) is a prescription medicine that works as a selective JAK1 and JAK2 inhibitor. It is used in the treatment of myelofibrosis, polycythemia vera, and certain cases of graft-versus-host disease (GVHD). By reducing abnormal JAK signaling, it helps control abnormal blood-cell production, decrease spleen enlargement, and relieve symptoms associated with these conditions. Treatment is given under medical supervision with regular monitoring.

Everyone Deserves Access to Life-saving Treatment Of Cancer. We are a Trusted Cancer Medicine seller delivering certified medications to every corner of the world.